ReviewFrontiers in endocrinology2025
Research progress in abnormal carbohydrate, lipid, and protein metabolism in children with isolated growth hormone deficiency.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genetic diversity and association analysis of the growth hormone gene in local Indonesian chicken.Journal of advanced veterinary and animal research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Growth hormone deficiency (GHD) is a rare endocrine disorder characterized by reduced or insufficient secretion of growth hormone (GH). GHD manifests with a heterogenous spectrum of symptoms mainly affecting musculoskeletal and endocrine system, with an increased predisposition to psychosocial disorders and ultimately reduced quality of life. Method: We searched the main databases for studies describing the metabolic effects of growth hormone and its deficiency. All full-text articles and major reviews were manually searched for additional studies. Result: Metabolic derangements of GHD are reported in carbohydrate (insulin resistance, diabetes mellitus), lipid (hypercholesterolemia, hypertriglyceridemia), and protein (decreased lean body mass) metabolism. Currently, recombinant growth hormone (rhGH) replacement therapy is the primary standard of care for the treatment of GHD. Understanding the impact of GH, including the effect of GHD and rhGH therapy, on metabolism would be a critical step in development of effective treatment and selecting the best management strategies. Discussion: This article reviews research progress and aims to offer new perspectives on the metabolic state of patients suffering from GHD and to compile data about the impact of rhGH therapy on metabolic pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.